Safety and Feasibility of the Supira System in High-Risk Percutaneous Coronary Interventions: 90-Day Results from the US SUPPORT I Early Feasibility Study (EFS)

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbott; Biotronik; Boston Scientific Corporation; Medtronic; Teleflex; Orbus Neich; Supira Medical</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - Boston Scientific Corporation; Medtronic; DeepQure; GoldenLeaf Medical</li></ul>